89581-84-0

Basic information

• Product Name: 2-BROMO-3-(CHLOROMETHYL)PYRIDINE
• Synonyms: 2-BROMO-3-(CHLOROMETHYL)PYRIDINE;2-Chloro-3-(chloroMethyl)...;Pyridine, 2-chloro-3-(chloroMethyl)-
• CAS NO: 89581-84-0
• Molecular Formula: C₆H₅Cl₂N
• Molecular Weight: 162.02
• EINECS: 145-896-5
• Mol File: 89581-84-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 250℃
• Flash Point: 129℃
• Appearance: /
• Density: 1.324
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.18±0.10(Predicted)
• CAS DataBase Reference: 2-BROMO-3-(CHLOROMETHYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-3-(CHLOROMETHYL)PYRIDINE(89581-84-0)
• EPA Substance Registry System: 2-BROMO-3-(CHLOROMETHYL)PYRIDINE(89581-84-0)

Safety Data

• Hazardous Substances Data: 89581-84-0(Hazardous Substances Data)

Usage

General Description

2-Bromo-3-(chloromethyl)pyridine is a chemical compound with the molecular formula C6H5BrClN. It is a pyridine derivative with a bromine and chloromethyl group attached to the third and fourth positions, respectively. 2-BROMO-3-(CHLOROMETHYL)PYRIDINE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is known to have antimicrobial properties and is used in the production of various pharmaceutical drugs, pesticides, and veterinary products. Additionally, it is also used as a building block in organic synthesis, particularly in the creation of complex molecules with biological activity. However, it is important to handle this compound with caution as it is considered to be toxic and hazardous to human health.

InChI:InChI=1/C6H5BrClN/c7-6-5(4-8)2-1-3-9-6/h1-3H,4H2

Upstream product

• 42330-59-6 (2-chloropyrid-3-yl)methanol 
• 18368-76-8 2 chloro-3-methylpyridine 
• 2942-59-8 2-chloronicotinic acid 
• 49609-84-9 2-Chloronicotinoyl chloride 
• 59-67-6 nicotinic acid 
• 36404-88-3 2-chloro-3-carbaldehydepyridine 

Downstream Products

• 205744-14-5 C-(2-chloro-pyridin-3-yl)-methylamine 
• 500732-63-8 [2-(3-benzyl-phenyl)-2-oxo-ethyl]-(2-chloro-pyridin-3-ylmethyl)-carbamic acid benzyl ester 
• 500732-65-0 7-(3-benzyl-benzoyl)-8-oxo-7,8-dihydro-5H-[1,6]naphthyridine-6-carboxylic acid benzyl ester 
• 500732-64-9 3-({benzyloxycarbonyl-[2-(3-benzyl-phenyl)-2-oxo-ethyl]-amino}-methyl)-pyridine-2-carboxylic acid methyl ester 
• 422550-94-5 1-[3-benzyl-5-(1,1-dioxoisothiazolidin-2-ylmethyl)-phenyl]-1-(8-hydroxy-[1,6]naphthyridin-7-yl)-methanone 
• 1026627-33-7 {2-[3-benzyl-5-(1,1-dioxo-isothiazolidin-2-ylmethyl)-phenyl]-2-oxo-ethyl}-(2-chloro-pyridin-3-ylmethyl)-carbamic acid benzyl ester 
• 422550-95-6 3-[({2-[3-benzyl-5-(1,1-dioxo-isothiazolidin-2-ylmethyl)-phenyl]-2-oxo-ethyl}-benzyloxycarbonyl-amino)-methyl]-pyridine-2-carboxylic acid ethyl ester 
• 101012-32-2 2-(2-chloropyridin-3-yl)acetonitrile 
• 1357305-91-9 3-(2-chloropyrid-3-ylmethoxy)-1-benzhydrylazetidine 
• 884049-52-9 spiro[piperidine-4,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 885031-86-7 tert-butyl 2'-oxo-1',2'-dihydro-1H-spiro[piperidine-4,3'-pyrrolo[2.3-b]pyridine]-1-carboxylate 
• 2942-59-8 2-chloronicotinic acid 
• 36404-88-3 2-chloro-3-carbaldehydepyridine 
• 1202068-01-6 1-((3S,4S)-1-[2-(2-fluoro-4-iodophenylamino)thieno[2,3-b]pyridine-3-carbonyl]-4-hydroxypyrrolidin-3-yl)-1-methyl-3-(9H-fluoren-9-ylmethoxycarbonyl)thiourea 

Relevant articles and documents

Structure-guided optimization of 1H-imidazole-2-carboxylic acid derivatives affording potent VIM-Type metallo-β-lactamase inhibitors

Production of metallo-β-lactamases (MBLs) in bacterial pathogens is an important cause of resistance to the ‘last-resort’ carbapenem antibiotics. Development of effective MBL inhibitors to reverse carbapenem resistance in Gram-negative bacteria is still needed. We herein report X-ray structure-guided optimization of 1H-imidazole-2-carboxylic acid (ICA) derivatives by considering how to engage with the active-site flexible loops and improve penetration into Gram-negative bacteria. Structure-activity relationship studies revealed the importance of appropriate substituents at ICA 1-position to achieve potent inhibition to class B1 MBLs, particularly the Verona Integron-encoded MBLs (VIMs), mainly by involving ingenious interactions with the flexible active site loops as observed by crystallographic analyses. Of the tested ICA inhibitors, 55 displayed potent synergistic antibacterial activity with meropenem against engineered Escherichia coli strains and even intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL. The morphologic and internal structural changes of bacterial cells after treatment further demonstrated that 55 crossed the outer membrane and reversed the activity of meropenem. Moreover, 55 showed good pharmacokinetic and safety profile in vivo, which could be a potential candidate for combating VIM-mediated Gram-negative carbapenem resistance.

DIFLUOROMETHYLENE COMPOUND

The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.

Fatty acid amide hydrolase inhibitors. 3: Tetra-substituted azetidine ureas with in vivo activity

We describe here our attempts to optimise the human fatty acid amide hydrolase (FAAH) inhibition and physicochemical properties of our previously reported tetrasubstituted azetidine urea FAAH inhibitor, VER-156084. We describe the SAR of a series of analogues and conclude with the demonstration of in vivo dose-dependant FAAH inhibition in an anandamide-loading study in rats.